Now for the High-Hanging Fruit
We should be thrilled with the success of the approved CD-19 CAR-T therapies. But the field is still young, and we are only scratching the surface of what’s possible.
Miguel Forte | | Opinion
Recent approvals from both regulatory agencies and health technology assessment bodies are showing that cell and gene therapies can be commercially successful. And though it’s right to be delighted that these fantastic technologies are beginning to treat and, in some cases, cure patients with life-threatening diseases, we should also recognize that the field is still in its infancy.
We are only just beginning to see the fruits of years’ of investigation into understanding the role of lymphocytes in controlling cancer – going all the way back to tumor-infiltrating lymphocytes. The question for the field has been how we can harness and direct the immune system to fight cancer. The field has shown that it is possible to put a chimeric antigen receptor (CAR) on a T-cell, have it recognize an antigen on the cancer cell and activate the intercellular machinery. CD19 is the target for both of the products on the market today and is really the core of the cell therapy field. The fact that it is only expressed in B-cells allows us to specially target cancers arising from this type of cell – such as B-cell lymphomas, acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine